Autologous Cell Therapy, Contract Cell Therapy Manufacturing

Dendreon is at the forefront of cellular therapy, focusing on innovative science to enhance patient outcomes through its unique cellular therapies. The company's flagship product, PROVENGE® (sipuleucel-T), represents a significant advancement in cancer treatment as the first FDA-approved cellular immunotherapy specifically designed for advanced prostate cancer. This therapy utilizes the patient's own immune cells, reprogramming them to identify and attack cancer cells, which has been shown to improve overall survival rates in clinical settings. Since its introduction in 2010, PROVENGE has been administered to nearly 40,000 men, demonstrating its effectiveness and paving the way for further research into its potential applications for other stages of prostate cancer.

In addition to its flagship product, Dendreon is committed to advancing the field of cellular therapy through comprehensive manufacturing and logistical support for other companies developing similar life-saving innovations. The company engages in clinical research and strategic partnerships to facilitate the development and production of next-generation cellular therapies. Dendreon's ongoing clinical trials, such as the ProVent Study, aim to explore the efficacy of PROVENGE in patients with lower-risk prostate cancer, showcasing the company's dedication to expanding treatment options and improving patient care in oncology.

United States

Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon’s flagship product, PROVENGE (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010. Dendreon also is evaluating the use of PROVENGE in early-stage prostate cancer, with the hope of curing more men of the disease. Dendreon is headquartered in Seal Beach, Calif.

Dendreon

Company Details